1. Quick Details:
Letrozole
Alias: Femara, Letrozole, TROZET
CAS Registry Number:112809-51-5
Purity: 98%
MF: C17H11N5
MW: 285.3
Character: White crystalline powder.
Manufacturer :Hezhong
Delivery time :within 18 hours upon receipt of payment
Delivery: EMS, DHL, TNT, FedEx, UPS
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
Usage: Letrozole is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body. Side effects from Letrozole include a lowered sex drive and continuous use can lead to lowered lipid function and an impaired immune system.
2. Product Description:
Product name |
Letrozole |
Other name |
Femara, Letrozole, TROZET |
CAS register number |
112809-51-5 |
Molecular formula |
C17H11N5 |
Molecular weight |
285.3 |
Molecular structure |
|
Assay |
98% |
Appearance |
White crystalline powder |
Package |
1kg/aluminium foil bag or as required |
Usage |
can be used as pharmaceutical material |
Minimum order quantity |
10g |
Shipping |
By express courier |
Shipping leading time |
Within 18 hours after receiving the payment |
Payment options |
Western unio, MoneyGram, T/T |
Price |
Negotiated |
3. Applications:
Letrozole has been used for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation. A Canadian study presented at the American Society of Reproductive Medicine 2005 Conference suggested that letrozole may increase the risk of birth defects.[citation needed] A more detailed ovulation induction follow-up study found that letrozole, compared with a control group of clomiphene, had significantly lower congenital malformations and chromosomal abnormalities at an overall rate of 2.4% (1.2% major malformations) compared with clomiphene 4.8% (3.0% major malformations). Despite this, India banned the usage of letrozole in 2011, citing potential risks to infants.In 2012, an Indian parliamentary committee said that the drug controller office colluded with letrozole's makers to approve the drug for infertility in India and also stated that letrozole's use for infertility was illegal worldwide; however, such off-label uses are legal in many countries such as the US and UK.